CD4 and neoplasm: This includes hypermethylation at CCL2, CD4, IFNG, and TNF, which may contribute to non-inflamed tumor microenvironment (TME) phenotypes and reduced efficacy of immune checkpoint inhibitors (ICIs) [172].